Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-05

Study Completion Date

2019-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the clinical efficacy of a combination of Astaxanthin (2 mg), Lycopene (1.8 mg), and d-alpha-Tocopherol (10 IU) in terms of its skin anti-aging properties. Specifically, the investigators aim to determine the increase in hydration levels of the skin, decrease in atypical skin pigmentation, and reduction of signs of photoaging, particularly facial fine lines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure

NCT03730649

Skin Aging

ACTIVE_NOT_RECRUITING EARLY_PHASE1

Evaluation of the Anti-aging Efficacy of Two Dietary Supplements

NCT06032598

Healthy Volunteers

COMPLETED NA

Efficacy of Topical Antioxidants in Tretment of Photoaging

NCT04835259

Photoaging

UNKNOWN NA

A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement Lumenato and Its Impact on Skin Parameters in Healthy Female Subjects

NCT04356456

Skin

WITHDRAWN NA

A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects

NCT04276753

Skin Aging

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Aging Wrinkles

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)

Group Type EXPERIMENTAL

Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)

Intervention Type DIETARY_SUPPLEMENT

The intervention is to be taken once daily, for 12 weeks.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

The intervention is to be taken once daily, for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)

The intervention is to be taken once daily, for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Placebo

The intervention is to be taken once daily, for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy individuals age 30 to 60 years old
* Fitzpatrick Skin Type I-IV
* Crow's Feet Wrinkle Scale Class 1-2
* Subjects willing to provide written informed consent

Exclusion Criteria

* Use of topical or oral anti-aging drug therapy 1 month prior to the study
* History of allergy to cosmetics and anti-aging drugs
* History of photosensitivity reactions
* Any current or past medical condition, including seizures and stroke
* History of pigmentation disorder such as but not limited to vitiligo and leukoderma
* Immunocompromised state
* Pregnant or lactating (pregnancy kit will be used to check)
* Patients who have undergone laser, radiofrequency, peeling, and other procedural therapies for anti-aging in the month prior to the study.
* Patients with current inflammatory or infectious skin disease on the face, or history of such in the month prior to the study.
* Patients taking OCDs and other photosensitizing drugs (e.g. tetracycline).
* Not willing to provide informed consent

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes